Menu Search
Equities

BIOAGE Labs Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
Y7G:MUN

BIOAGE Labs Inc

Actions
  • Price (EUR)17.00
  • Today's Change-0.40 / -2.30%
  • Shares traded5.00
  • 1 Year change+316.67%
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2026 08:22 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

  • Revenue in USD (TTM)5.92m
  • Net income in USD-75.79m
  • Incorporated2015
  • Employees62.00
  • Location
    BIOAGE Labs Inc5885 Hollis Street, Suite 370EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 806-1445
  • Websitehttps://bioagelabs.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.